Home LiteratureArticle Details
PMID: 6404817 Published · ppublish English Journal Article

Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide.

Infection and immunity ·Vol. 39 ·No. 3 ·1983-03-00 ·Pages 1072-9

Cryz SJ, Fürer E, Germanier R

Abstract

The protective capacity of passively transferred immunoglobulin G (IgG) fractions from antitoxin (AT-IgG), antielastase (AE-IgG), and antilipopolysaccharide (ALPS-IgG) against Pseudomonas aeruginosa infection was evaluated in a murine burn wound sepsis model. Complete protection was afforded by homologous ALPS-IgG against intermediate challenge doses (10 50% lethal doses) of P. aeruginosa PA220, whereas AT-IgG and AE-IgG offered no significant protection (P less than 0.5). The simultaneous transfer of AT-IgG or AE-IgG with ALPS-IgG gave no additional protection above that seen with ALPS-IgG alone. The transfer of ALPS-IgG did not dramatically alter bacterial multiplication in the skin at the site of infection. However, bacteremia and infection of the liver were prevented. In parallel experiments, AT-IgG or AE-IgG did not significantly alter either the course of the infection or the number of bacteria seen in the blood, liver, or skin when compared with controls. ALPS-IgG administered 24 h before infection, at the time of infection, or 4 h postinfection provided complete protection. Even when ALPS-IgG was transferred at a time when the infection was well established locally in the skin (8 h postinfection), highly significant protection (P greater than 0.999) was obtained. Protection afforded by ALPS-IgG was serotype specific. These results indicate that antibody to lipopolysaccharide is of critical importance for protection against P. aeruginosa challenge in a relevant animal model.

MeSH Terms
ADP Ribose Transferases Animals Antitoxins/immunology Bacterial Toxins Burns/complications Disease Models, Animal Exotoxins/immunology Immunization, Passive Immunoglobulin G Lipopolysaccharides/immunology Liver/microbiology Mice Pancreatic Elastase/immunology Pseudomonas Infections/complications,immunology Pseudomonas aeruginosa/growth & development Sepsis/prevention & control Skin/microbiology Time Factors Virulence Factors
Chemicals
Antitoxins Bacterial Toxins Exotoxins Immunoglobulin G Lipopolysaccharides Virulence Factors ADP Ribose Transferases toxA protein, Pseudomonas aeruginosa Pancreatic Elastase
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Cryz S J
Fürer E
Germanier R
References (39)
39 references, click to expand
  1. Human immunity to Pseudomonas aeruginosa. II. Relationship between heat-stable opsonins and type-specific lipopolysaccharides.
    J Infect Dis. 1972 Sep;126(3):277-87 PMID: 4626510
  2. Type-specific immunity in pseudomonas diseases.
    J Lab Clin Med. 1972 Jan;79(1):47-54 PMID: 4621414
  3. Controlled prospective trial of Pseudomonas aeruginosa vaccine in children with acute leukemia.
    Cancer. 1973 Oct;32(4):761-6 PMID: 4201654
  4. Corneal ulcers caused by protease and elastase from Pseudomonas aeruginosa.
    Jpn J Exp Med. 1974 Oct;44(5):435-42 PMID: 4215914
  5. Burn wounds: microbiology, local host defenses, and current therapy.
    CRC Crit Rev Clin Lab Sci. 1973 Jul;4(1):61-100 PMID: 4614939
  6. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model.
    J Infect Dis. 1975 Jun;131(6):688-91 PMID: 805812
  7. NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin,.
    Proc Natl Acad Sci U S A. 1975 Jun;72(6):2284-8 PMID: 166383
  8. Effects of protease and elastase from Pseudomonas aeruginosa on skin.
    Jpn J Exp Med. 1975 Apr;45(2):79-88 PMID: 819684
  9. Large-scale purification and characterization of the exotoxin of Pseudomonas aeruginosa.
    Infect Immun. 1976 Oct;14(4):1077-86 PMID: 11187
  10. Neutralizing antibody to Pseudomonas aeruginosa exotoxin in human sera: evidence for in vivo toxin production during infection.
    Infect Immun. 1976 Oct;14(4):942-7 PMID: 825470
  11. A new polyvalent Pseudomonas vaccine.
    J Med Microbiol. 1977 Feb;10(1):19-27 PMID: 402473
  12. Drug resistance in relation to use of silver sulphadiazine cream in a burns unit.
    J Clin Pathol. 1977 Feb;30(2):160-4 PMID: 321478
  13. Pseudomonas aeruginosa infection in cystic fibrosis. Bactericidal effect of serum from normal individuals and patients with cystic fibrosis on P. aeruginosa strains from patients with cystic fibrosis or other diseases.
    Acta Pathol Microbiol Scand C. 1977 Apr;85(2):107-14 PMID: 404841
  14. Passive protection by antitoxin in experimental Pseudomonas aeruginosa burn infections.
    Infect Immun. 1977 Dec;18(3):596-602 PMID: 412786
  15. Role of exotoxin and protease as possible virulence factors in experimental infections with Pseudomonas aeruginosa.
    Infect Immun. 1978 Mar;19(3):839-45 PMID: 417031
  16. Isolation and characterization of a high-molecular-weight polysaccharide from the slime of Pseudomonas aeruginosa.
    Infect Immun. 1978 Dec;22(3):908-18 PMID: 103840
  17. Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosa.
    Infect Immun. 1978 Dec;22(3):919-25 PMID: 103841
  18. Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man.
    J Clin Invest. 1979 Feb;63(2):276-86 PMID: 429553
  19. Influence of iron on yields of extracellular products in Pseudomonas aeruginosa cultures.
    J Bacteriol. 1979 Apr;138(1):193-200 PMID: 108250
  20. Assessment of protease (elastase) as a Pseudomonas aeruginosa virulence factor in experimental mouse burn infection.
    Infect Immun. 1979 Apr;24(1):181-7 PMID: 110690
  21. Evaluation of Pseudomonas aeruginosa toxin A in experimental rat burn wound sepsis.
    Infect Immun. 1979 Sep;25(3):828-30 PMID: 500188
  22. Controlled trials of a polyvalent pseudomonas vaccine in burns.
    Lancet. 1979 Nov 10;2(8150):977-82 PMID: 91774
  23. Evidence for the role of toxin A in the pathogenesis of infection with Pseudomonas aeruginosa in humans.
    J Infect Dis. 1980 Oct;142(4):538-46 PMID: 6777437
  24. Corneal infections in mice with toxin A and elastase mutants of Pseudomonas aeruginosa.
    J Infect Dis. 1980 Oct;142(4):547-55 PMID: 6904461
  25. Protection against experimental Pseudomonas aeruginosa infection in mice by active immunization with exotoxin A toxoids.
    Infect Immun. 1981 May;32(2):681-9 PMID: 6788700
  26. Effect of formalin toxoiding on Pseudomonas aeruginosa toxin A: biological, chemical, and immunochemical studies.
    Infect Immun. 1981 May;32(2):759-68 PMID: 6265363
  27. Preparation and characterization of detoxified lipopolysaccharide-protein conjugates.
    J Biol Chem. 1981 Jul 25;256(14):7305-10 PMID: 6166612
  28. High-molecular-weight polysaccharide antigen from Pseudomonas aeruginosa immunotype 2.
    Infect Immun. 1981 Nov;34(2):461-8 PMID: 6171520
  29. Flagellar preparations from Pseudomonas aeruginosa: animal protection studies.
    Infect Immun. 1982 Jan;35(1):276-80 PMID: 6797948
  30. Protective effect of muramyl dipeptide analogs against infections of Pseudomonas aeruginosa or Candida albicans in mice.
    Infect Immun. 1981 Dec;34(3):676-83 PMID: 7333666
  31. Protection against colibacillosis in neonatal piglets by immunization of dams with procholeragenoid.
    Infect Immun. 1982 Mar;35(3):887-94 PMID: 7040250
  32. Contribution of toxin A and elastase to virulence of Pseudomonas aeruginosa in chronic lung infections of rats.
    Infect Immun. 1982 Jun;36(3):1223-8 PMID: 6807846
  33. Antibody response to Pseudomonas aeruginosa exoproducts in cancer patients.
    J Clin Microbiol. 1982 Jan;15(1):115-22 PMID: 6821202
  34. Protein measurement with the Folin phenol reagent.
    J Biol Chem. 1951 Nov;193(1):265-75 PMID: 14907713
  35. PSEUDOMONAS AERUGINOSA ELASTASE. ISOLATION, CRYSTALLIZATION, AND PRELIMINARY CHARACTERIZATION.
    J Biol Chem. 1965 Aug;240:3295-304 PMID: 14321366
  36. Immunological determinants of pseudomonas infections of man accompanying severe burn injury.
    J Trauma. 1970 Jul;10(7):565-74 PMID: 4986708
  37. Pseudomonas bacteremia in patients with malignant diseases.
    Am J Med Sci. 1970 Oct;60(4):216-23 PMID: 4322162
  38. Isolation and characterization of antigenic components of a new heptavalent Pseudomonas vaccine.
    Nat New Biol. 1971 Feb 17;229(7):209-10 PMID: 5281014
  39. Clinical evaluation of Pseudomonas hyperimmune globulin.
    J Surg Res. 1973 Feb;14(2):87-96 PMID: 4632770
Article Info
Journal
Infection and immunity
Abbr.
Infect Immun
ISSN
0019-9567
Published
1983-03-00
Pages
1072-9
Language
English
Region
United States
NLM ID
0246127
PMCID
PMC348065
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com